Contemporary role of androgen deprivation therapy for prostate cancer - Wikidata - awgldk - TriplyDB

Contemporary role of androgen deprivation therapy for prostate cancer

Contemporary role of androgen deprivation therapy for prostate cancer

http://www.wikidata.org/entity/Q34211155

about

Quality of life effects of androgen deprivation therapy in a prostate cancer cohort in New Zealand: can we minimize effects using a stratification based on the aldo-keto reductase family 1, member C3 rs12529 gene polymorphism?Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer.Elevated YKL40 is associated with advanced prostate cancer (PCa) and positively regulates invasion and migration of PCa cells N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor.Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study.The course of metastatic prostate cancer under treatment.Gonadotropin-releasing hormone agonist overuse: urologists' response to reimbursement and characteristics associated with persistent overuse Multimorbidity Patterns in Hospitalized Older Patients: Associations among Chronic Diseases and Geriatric Syndromes.Androgen deprivation therapy and fracture risk in Chinese patients with prostate carcinoma.Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer?Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy Androgen-deprivation therapy alone versus combined with radiation therapy or chemotherapy for nonlocalized prostate cancer: a systematic review and meta-analysis Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer.Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer Group-based exercise in daily clinical practice to improve physical fitness in men with prostate cancer undergoing androgen deprivation therapy: study protocol.Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer.Survivorship after prostate cancer treatment: spouses' quality of life at 36 months.The androgen/androgen receptor axis in prostate cancer.Management of advanced prostate cancer in senior adults: the new landscape.Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics.Novel therapeutic approaches for the treatment of castration-resistant prostate cancer.Optimal pharmacotherapeutic management of hormone-sensitive metastatic prostate cancer.Bone health care for patients with prostate cancer receiving androgen deprivation therapy.Advances in local and ablative treatment of oligometastasis in prostate cancer.Adverse effects of androgen-deprivation therapy in prostate cancer and their management.Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development.Pharmacokinetics, pharmacodynamics and clinical efficacy of abiraterone acetate for treating metastatic castration-resistant prostate cancer.Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners.Exercise overcome adverse effects among prostate cancer patients receiving androgen deprivation therapy: An update meta-analysis The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.Long-term cancer control outcomes of robot-assisted radical prostatectomy for prostate cancer treatment: a meta-analysis.AZD1152-HQPA induces growth arrest and apoptosis in androgen-dependent prostate cancer cell line (LNCaP) via producing aneugenic micronuclei and polyploidy.Hormone therapy for prostate cancer increases the risk of Alzheimer's disease: a nationwide 4-year longitudinal cohort study.Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts.PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality.Clinical presentation and predictors of survival related to extent of bone metastasis in 900 prostate cancer patients.

P2860

Q28385758-E40F1EE9-D13F-4BFF-8B2B-0707762C0F44 Q33775723-6C367E7F-1A55-45C3-837A-F63AC3FE69E1 Q34052057-F60D3338-7820-48F7-BFF2-1DB95B4D0965 Q34749943-97B896CA-4FD3-4BD2-BB6F-BEE96E88BC84 Q34984105-9B25F690-F273-4B88-9AC0-04207BA46F3A Q35059214-7BCEA14A-8112-4FD4-94FA-B2A6586C1CFF Q35602510-19B129FF-5C80-48C7-AF11-55D4221FCFAC Q35711631-F6EFA25C-49C6-4FB3-9A86-0E7E3D1F898F Q36269807-579D0DB2-17B8-44AF-BD05-FAACE6200001 Q36319986-8CF34BBE-8462-4F31-A26A-451B7E5C6540 Q36387830-85292EDC-3B5E-41DD-9BEE-01B4909F5E62 Q36530173-8E15D01D-62DD-4364-BF3C-214F53CD9F24 Q36604092-0A37C389-B8FD-4C4E-8F05-BEBFBDF7A0BD Q36751550-66DB3496-2CCE-4A05-9776-1C870E9EBA87 Q37046523-EB03DE75-719A-4CEB-9B30-2A9751578875 Q37063622-9BF77E96-0D3B-4578-B1E6-7C71798E667E Q37105407-B8C05620-299F-404E-9386-6050EDAE941E Q37322621-B7EDB32A-2FD6-4A28-8743-D3318B6EE52B Q37596760-BF314EE5-BCA6-40CB-A2E7-587D3F4E1BD9 Q37619132-3C22D6A7-6599-4883-B8ED-2074ADC13730 Q37983462-6340F80B-2E31-49D2-8AF8-EFA7B5A06F63 Q38046826-4A6D9045-ED65-46A4-A247-DAAD077547EC Q38067916-A9A5931C-5261-4E9D-8E9F-3C8A6A13D676 Q38106640-C36EED51-81AD-4993-88A5-7B8BDB8929B0 Q38116358-ACB9A7D9-F535-4DD1-B83E-68AED1A7DA25 Q38130174-7290DFD2-CC1B-476A-BA8E-A756C4E66C87 Q38207463-7302D5D5-C3D7-40D4-8AD8-BFAD298567AD Q38243113-3B4305C4-DCB0-48C2-B9C3-7EC84129B24B Q38261253-8558FE9A-D805-4769-AD6A-303DDC815DAB Q38262816-D50DE671-0AFD-4B28-A07F-EE3F087B1C0F Q38455793-9A28B9DB-BB30-4C17-964F-B51B05D97BE1 Q38587219-E4928B57-58A9-48DA-82A0-22E9EB36B840 Q38691070-6A679046-A5B2-4E12-9A8B-C9DFF19300BD Q38817011-43BBFE9A-59C3-41CF-A938-B592E75315AA Q38941692-4AF841B3-41FB-4996-9879-BE2F07F0F585 Q38951017-47AFE103-A9AD-4E55-9509-C8C96388E670 Q39032138-D12B1B76-FB0C-47BA-A20F-45A05E90A940 Q39100169-761145DB-E8DF-4E91-AA6F-945BC8BDB1D7 Q39181062-D1524CCB-88EB-4EE5-BC6A-4EDDACD82DA5 Q40591427-FD14AF7B-857B-4A92-A750-5F8B72A9C319

P2860

Contemporary role of androgen deprivation therapy for prostate cancer

http://www.wikidata.org/entity/Q34211155

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Contemporary role of androgen deprivation therapy for prostate cancer

@ast

Contemporary role of androgen deprivation therapy for prostate cancer

@en

Contemporary role of androgen deprivation therapy for prostate cancer

@nl

type

label

Contemporary role of androgen deprivation therapy for prostate cancer

@ast

Contemporary role of androgen deprivation therapy for prostate cancer

@en

Contemporary role of androgen deprivation therapy for prostate cancer

@nl

prefLabel

Contemporary role of androgen deprivation therapy for prostate cancer

@ast

Contemporary role of androgen deprivation therapy for prostate cancer

@en

Contemporary role of androgen deprivation therapy for prostate cancer

@nl

P1433

Q34211155-65D70DE8-FFCB-4CD5-9144-4820910F8167

P1476

Q34211155-E1FC27EA-4101-4424-82DC-68E647058385

P2093

Q34211155-1C9C7A8D-CFB3-49B7-90CA-7C2F150EF83A

Q34211155-2563FEB8-B102-4306-AF01-B6655184B8D6

Q34211155-25D6788E-332C-4064-907A-B250AA19B27B

Q34211155-7513647B-7978-41D1-8DAF-7D586730B83E

Q34211155-780E8514-9B8C-422F-97AB-9E41B1D1A97D

Q34211155-7F9D2652-DD30-4C41-BA26-1DDB8298E0AD

Q34211155-8EA6B515-F317-4BDF-A975-E78E84EE13FA

P2860

Q34211155-08909088-E952-422F-AB6A-7948DB584FD5

Q34211155-0A843CC9-5893-4B70-8F0A-C1ACCE2E09BC

Q34211155-0C8AE501-E589-4C7A-A002-6727DFAEDE50

Q34211155-0D69FAC8-B2FA-452B-B2B6-9E13584AD04C

Q34211155-0DE0759E-0892-4CA3-AF9A-F543B5CAFC4F

Q34211155-144602E4-36F2-408B-AC49-AD3DEF2760C2

Q34211155-162E3359-0777-47B7-A7C9-1E43AAF830C3

Q34211155-1EEB46E8-A1DA-4548-A303-D54A77A45017

Q34211155-2218157D-1BF6-475E-BB24-269D351D8E02

Q34211155-2D63A994-A164-4082-BAB8-F4A27088827E

P304

Q34211155-BD6ED242-FF37-4ED6-9CE1-78D3A7125775

P31

Q34211155-BDDE9AEB-59AE-4557-8BC5-954BE1CB0390

P356

Q34211155-6FCE7B12-09ED-4FED-8155-E4DFC356DB49

P407

Q34211155-AABA946A-B876-4826-9D90-468360AEA5D5

P433

Q34211155-C27C1CE4-59E1-4796-97D2-F7E2C152BB5D

P478

Q34211155-CDE7817D-5C1C-4794-BDC1-30FAC1DD77B3

P577

Q34211155-01DD18AF-09E7-4072-89BC-E645DF490F01

P5875

Q34211155-08C3BF29-B0DD-4B9E-A0A0-23AEB0076149

P698

Q34211155-577E7A27-98C6-4823-9C60-BB764E6811F3

P932

Q34211155-85BE8CCD-FAAE-47FE-A4E0-54E05E34553A

P356

J.EURURO.2011.08.026

P1433

European Urology

P1476

Contemporary role of androgen deprivation therapy for prostate cancer

@en

P2093

Cora N Sternberg

http://www.w3.org/2001/XMLSchema#string

Fritz H Schröder

http://www.w3.org/2001/XMLSchema#string

Mario A Eisenberger

http://www.w3.org/2001/XMLSchema#string

Nicolas Mottet

http://www.w3.org/2001/XMLSchema#string

Sergio Bracarda

http://www.w3.org/2001/XMLSchema#string

Urs E Studer

http://www.w3.org/2001/XMLSchema#string

Vincenzo Pagliarulo

http://www.w3.org/2001/XMLSchema#string

P2860

Intermittent versus continuous androgen suppression for prostatic cancer

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Metabolic complications of androgen deprivation therapy for prostate cancer

Abiraterone and increased survival in metastatic prostate cancer

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions

Is the flare phenomenon clinically significant?

National practice patterns and time trends in androgen ablation for localized prostate cancer.

P304

11-25

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2011.08.026

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51599761

http://www.w3.org/2001/XMLSchema#string

P698

21871711

http://www.w3.org/2001/XMLSchema#string

P932

3483081

http://www.w3.org/2001/XMLSchema#string